Huge trial on our core work, catch-up here
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
Huge trial on our core work, catch-up here
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) July 31, 2023
✳️10 tweets #NephJC catch-up ✳️
🌟Let’s recap the CONVINCE trial which pitted HDF against HD
🌟Do we now have CONVINCE-ing evidence for the superiority of convection added to diffusion? pic.twitter.com/92gW0zKv76